{
    "id": 11340,
    "fullName": "TPM3 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TPM3-ALK results from the fusion of TPM3 and ALK, and leads to constitutive Alk phosphoryltaion, cell transformation in culture, and tumorigenisis in animal models (PMID: 10934142, PMID: 15208656). TPM3-ALK fusions have been identified in inflammatory myofibroblastic tumors (PMID: 10934142), anaplastic large cell lymphoma (PMID: 10216106), and renal cell carcinoma (PMID: 32102128).",
            "references": [
                {
                    "id": 11167,
                    "pubMedId": 15208656,
                    "title": "Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15208656"
                },
                {
                    "id": 18436,
                    "pubMedId": 32102128,
                    "title": "Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32102128"
                },
                {
                    "id": 3597,
                    "pubMedId": 10934142,
                    "title": "TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10934142"
                },
                {
                    "id": 11165,
                    "pubMedId": 10216106,
                    "title": "A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10216106"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7170,
        "geneSymbol": "TPM3",
        "terms": [
            "TPM3",
            "CAPM1",
            "CFTD",
            "HEL-189",
            "HEL-S-82p",
            "hscp30",
            "NEM1",
            "OK/SW-cl.5",
            "TM-5",
            "TM3",
            "TM30",
            "TM30nm",
            "TM5",
            "TPM3nu",
            "TPMsk3",
            "TRK"
        ]
    },
    "variant": "TPM3 - ALK",
    "createDate": "09/03/2015",
    "updateDate": "03/25/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 12933,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "TPM3-ALK fusions aid the diagnosis of inflammatory myofibroblastic tumor (NCCN.org).",
            "molecularProfile": {
                "id": 11389,
                "profileName": "TPM3 - ALK"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8958,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with inflammatory myofibroblastic tumor that had progressed on Xalkori (crizotinib) achieved a partial response following treatment with Zykadia (ceritinib), and was found to harbor a TPM3-ALK fusion (PMID: 27742657).",
            "molecularProfile": {
                "id": 11389,
                "profileName": "TPM3 - ALK"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6806,
                    "pubMedId": 27742657,
                    "title": "Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27742657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11389,
            "profileName": "TPM3 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 6484,
                    "name": "ALK Inhibitor",
                    "profileName": "TPM3 - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}